JP4187275B2 - 血液製剤から希少細胞を採集する方法 - Google Patents
血液製剤から希少細胞を採集する方法 Download PDFInfo
- Publication number
- JP4187275B2 JP4187275B2 JP54293298A JP54293298A JP4187275B2 JP 4187275 B2 JP4187275 B2 JP 4187275B2 JP 54293298 A JP54293298 A JP 54293298A JP 54293298 A JP54293298 A JP 54293298A JP 4187275 B2 JP4187275 B2 JP 4187275B2
- Authority
- JP
- Japan
- Prior art keywords
- porous medium
- cells
- rare cells
- rare
- eluent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000010836 blood and blood product Substances 0.000 title claims abstract description 65
- 229940125691 blood product Drugs 0.000 title claims abstract description 65
- 210000004027 cell Anatomy 0.000 claims abstract description 326
- 238000000034 method Methods 0.000 claims abstract description 107
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 17
- 210000005087 mononuclear cell Anatomy 0.000 claims abstract description 6
- 235000015097 nutrients Nutrition 0.000 claims abstract description 3
- 239000002609 medium Substances 0.000 claims description 223
- 239000003480 eluent Substances 0.000 claims description 102
- 230000000717 retained effect Effects 0.000 claims description 38
- 210000000265 leukocyte Anatomy 0.000 claims description 27
- 210000003714 granulocyte Anatomy 0.000 claims description 25
- 210000004698 lymphocyte Anatomy 0.000 claims description 25
- 238000011010 flushing procedure Methods 0.000 claims description 15
- 210000000130 stem cell Anatomy 0.000 claims description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 8
- 229940098773 bovine serum albumin Drugs 0.000 claims description 7
- 229920002307 Dextran Polymers 0.000 claims description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 238000010828 elution Methods 0.000 abstract description 20
- 239000012530 fluid Substances 0.000 abstract description 9
- 238000003306 harvesting Methods 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 239000001963 growth medium Substances 0.000 description 17
- 150000001768 cations Chemical class 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 238000000926 separation method Methods 0.000 description 15
- 230000014759 maintenance of location Effects 0.000 description 14
- 239000012190 activator Substances 0.000 description 13
- 239000000306 component Substances 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 238000011144 upstream manufacturing Methods 0.000 description 11
- 239000000758 substrate Substances 0.000 description 9
- 239000011859 microparticle Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 230000035605 chemotaxis Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000010419 fine particle Substances 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 210000001539 phagocyte Anatomy 0.000 description 4
- 239000007320 rich medium Substances 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920002292 Nylon 6 Polymers 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000004423 amoeboid cell Anatomy 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000003399 chemotactic effect Effects 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000001617 migratory effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002955 secretory cell Anatomy 0.000 description 3
- RSGFPIWWSCWCFJ-VAXZQHAWSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O RSGFPIWWSCWCFJ-VAXZQHAWSA-N 0.000 description 2
- 231100000699 Bacterial toxin Toxicity 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 2
- 239000000688 bacterial toxin Substances 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000036978 cell physiology Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- YBLJYSTXRAWBBH-PZRMXXKTSA-N (2s,3r,4s,5r,6r)-6-(hydroxymethyl)-2-methyloxane-2,3,4,5-tetrol Chemical compound C[C@]1(O)O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YBLJYSTXRAWBBH-PZRMXXKTSA-N 0.000 description 1
- YBLJYSTXRAWBBH-ZFYZTMLRSA-N (2s,3r,4s,5s,6r)-6-(hydroxymethyl)-2-methyloxane-2,3,4,5-tetrol Chemical compound C[C@]1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YBLJYSTXRAWBBH-ZFYZTMLRSA-N 0.000 description 1
- YBLJYSTXRAWBBH-VEIUFWFVSA-N (2s,3s,4s,5s,6r)-6-(hydroxymethyl)-2-methyloxane-2,3,4,5-tetrol Chemical compound C[C@]1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O YBLJYSTXRAWBBH-VEIUFWFVSA-N 0.000 description 1
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920000571 Nylon 11 Polymers 0.000 description 1
- 229920000299 Nylon 12 Polymers 0.000 description 1
- 229920000305 Nylon 6,10 Polymers 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 229920000572 Nylon 6/12 Polymers 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 238000003320 cell separation method Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 229940119743 dextran 70 Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012090 serum-supplement Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4320097P | 1997-04-08 | 1997-04-08 | |
| US60/043,200 | 1997-04-08 | ||
| US6411197P | 1997-11-03 | 1997-11-03 | |
| US60/064,111 | 1997-11-03 | ||
| US6419297P | 1997-11-04 | 1997-11-04 | |
| US60/064,192 | 1997-11-04 | ||
| PCT/US1998/006643 WO1998045413A1 (en) | 1997-04-08 | 1998-04-03 | Method of harvesting rare cells from blood products |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001518792A JP2001518792A (ja) | 2001-10-16 |
| JP2001518792A5 JP2001518792A5 (enExample) | 2005-11-10 |
| JP4187275B2 true JP4187275B2 (ja) | 2008-11-26 |
Family
ID=27366293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54293298A Expired - Lifetime JP4187275B2 (ja) | 1997-04-08 | 1998-04-03 | 血液製剤から希少細胞を採集する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6544751B1 (enExample) |
| EP (2) | EP1690930A1 (enExample) |
| JP (1) | JP4187275B2 (enExample) |
| AT (1) | ATE329012T1 (enExample) |
| AU (1) | AU6795498A (enExample) |
| CA (1) | CA2286156C (enExample) |
| DE (1) | DE69834809T2 (enExample) |
| WO (1) | WO1998045413A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040224300A1 (en) * | 1997-01-24 | 2004-11-11 | Shuji Terashima | Method for separating nucleated cells |
| ATE329012T1 (de) * | 1997-04-08 | 2006-06-15 | Pall Corp | Verfahren zur gewinnung von seltenen zellen aus blutprodukten |
| US7745106B2 (en) * | 1997-06-24 | 2010-06-29 | Cascade Medical Enterprises, Llc | Methods and devices for separating liquid components |
| US6979307B2 (en) * | 1997-06-24 | 2005-12-27 | Cascade Medical Enterprises Llc | Systems and methods for preparing autologous fibrin glue |
| EP1916297B1 (en) * | 2001-04-10 | 2010-12-29 | BioE LLC | Cell separation compositions and methods |
| US7074440B2 (en) * | 2002-05-01 | 2006-07-11 | Rulin Xiu | Compositions and methods for body weight loss |
| HUE031517T2 (en) * | 2002-06-19 | 2017-07-28 | Northwest Biotherapeutics Inc | Cross-flow filtration equipment and procedures for leukocyte enrichment |
| US7291450B2 (en) * | 2003-03-28 | 2007-11-06 | Smith & Nephew, Inc. | Preparation of a cell concentrate from a physiological solution |
| US20050208501A1 (en) | 2004-03-16 | 2005-09-22 | Ambion, Inc. | Process and reagents for extraction of RNA from fractionated blood leukocytes |
| US20060234210A1 (en) * | 2004-04-14 | 2006-10-19 | Affinergy, Inc. | Filtration device and method for removing selected materials from biological fluids |
| US20060064070A1 (en) * | 2004-09-07 | 2006-03-23 | Jeffrey Martin | Methods and devices for sterile field transfer |
| EP1833452A1 (en) * | 2004-11-23 | 2007-09-19 | Smith and Nephew, Inc. | Composite mixer |
| CA2592381A1 (en) * | 2004-12-16 | 2006-06-22 | Idexx Laboratories, Inc. | Apparatus and method to elute microorganisms from a filter |
| WO2006076567A2 (en) * | 2005-01-13 | 2006-07-20 | Micronics, Inc. | Microfluidic rare cell detection device |
| US8979770B2 (en) * | 2006-02-24 | 2015-03-17 | Merck Sharp & Dohme Corp. | Extraction and diagnostic fluid devices, systems and methods of use |
| US7598089B2 (en) * | 2006-04-19 | 2009-10-06 | Bioe, Inc. | Methods and compositions for separating cells |
| US7713688B2 (en) * | 2007-01-26 | 2010-05-11 | Bioe, Llc | Methods and compositions for depleting specific cell populations from blood tissues |
| KR20090121297A (ko) | 2007-03-02 | 2009-11-25 | 스미쓰 앤드 네퓨 피엘씨 | 생물학적 시료의 여과시 초음파, 역세정 및 필터 이동에 의한 필터 세정용 기기 및 방법 |
| US8546127B2 (en) * | 2008-06-30 | 2013-10-01 | General Electric Company | Bacteria/RNA extraction device |
| US8158405B2 (en) * | 2008-06-30 | 2012-04-17 | General Electric Company | Process for concentrating and processing fluid samples |
| WO2010012002A1 (en) * | 2008-07-25 | 2010-01-28 | Saryna Medical Corporation | Methods and systems for genetic analysis of fetal nucleated red blood cells |
| US8961787B2 (en) | 2008-12-01 | 2015-02-24 | General Electric Company | Systems and methods for processing complex biological materials |
| US20100151438A1 (en) * | 2008-12-12 | 2010-06-17 | General Electric Company | Methods and kits for enhancing sedimentation and recovery of cells in a sample |
| US20100210989A1 (en) | 2008-12-23 | 2010-08-19 | Janet Lesley Macpherson | Processing blood |
| US9649424B2 (en) | 2009-06-30 | 2017-05-16 | Kaneka Corporation | Blood component separation system and separation material |
| US9034280B2 (en) * | 2009-12-16 | 2015-05-19 | General Electric Corporation | High-throughput methods and systems for processing biological materials |
| EP2363501A1 (en) * | 2010-03-02 | 2011-09-07 | Universitätsklinikum Hamburg-Eppendorf | Method for isolating target cells |
| US8774488B2 (en) | 2010-03-11 | 2014-07-08 | Cellscape Corporation | Method and device for identification of nucleated red blood cells from a maternal blood sample |
| US20130323712A1 (en) | 2010-11-25 | 2013-12-05 | Kaneka Corporation | Method and material for separating leukocytes or mononuclear cells |
| JP2012120458A (ja) * | 2010-12-06 | 2012-06-28 | Kaneka Corp | 細胞の分離器具。 |
| US20130143195A1 (en) | 2011-12-05 | 2013-06-06 | Pall Corporation | Leukocyte purification |
| US9427512B2 (en) | 2012-06-08 | 2016-08-30 | Pall Corporation | Filter device |
| US9421317B2 (en) | 2012-06-08 | 2016-08-23 | Pall Corporation | Cell harvesting device and system |
| GB201306810D0 (en) | 2013-04-15 | 2013-05-29 | Cells4Life Group Llp | Methods of cell separation |
| WO2017100782A1 (en) | 2015-12-11 | 2017-06-15 | Research Institute At Nationwide Children's Hospital | Systems and methods for optimized patent specific tissue engineering vascular grafts |
| US10940248B2 (en) * | 2016-12-19 | 2021-03-09 | Fenwal, Inc. | Systems and methods for recovering white blood cells from a leukoreduction filter |
| US20230258663A9 (en) | 2019-05-02 | 2023-08-17 | Kellbenx Incorporated | Filtration-based methods for preparing fetal nucleated red blood cells (nrbcs) for diagnostic testing |
| CN111454902B (zh) * | 2020-04-08 | 2022-12-02 | 郭华 | 血液分离富集白细胞、干细胞和/或病原体的方法及装置 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4070243A (en) * | 1976-08-30 | 1978-01-24 | University Of Illinois Foundation | Method for distinguishing subpopulations in a population of morphologically indistinguishable cells |
| GB2018151B (en) | 1978-03-06 | 1982-12-08 | Asahi Chemical Ind | Seperation of leukocytes from leukocyte-containing suspension by filtration |
| US4255267A (en) * | 1979-11-02 | 1981-03-10 | E. I. Du Pont De Nemours And Company | Separation and recovery of granulocytes from blood using adherence on an expandable bed of a polymeric material |
| JPS57145662A (en) | 1981-03-02 | 1982-09-08 | Asahi Chemical Ind | Filter, method and apparatus for sampling white corpuscle component |
| US4500509A (en) * | 1981-03-11 | 1985-02-19 | Lawrence Kass | Metachromatic dye sorption and fluorescent light emmisive means for differential determination of developmental stages of neutrophilic granulocytic cells and other leukocytes |
| US4448879A (en) * | 1981-03-26 | 1984-05-15 | Hooper Trading Company | High yield process for in vitro production of serum-free and mitogen-free interleukin-2 |
| US4645738A (en) * | 1983-09-30 | 1987-02-24 | Memorial Sloan-Kettering Institute Cancer Center | Method for differential diagnosis of T cell leukemias using monoclonal antibodies |
| US4714680B1 (en) | 1984-02-06 | 1995-06-27 | Univ Johns Hopkins | Human stem cells |
| US4965204A (en) | 1984-02-06 | 1990-10-23 | The Johns Hopkins University | Human stem cells and monoclonal antibodies |
| JPS63127765A (ja) | 1986-11-17 | 1988-05-31 | テルモ株式会社 | 濾過器 |
| US4923620A (en) | 1987-10-20 | 1990-05-08 | Pall Corporation | Device for depletion of the leukocyte content of blood and blood components |
| GB2231282B (en) | 1989-05-09 | 1993-08-04 | Pall Corp | Device and method for depletion of the leucocyte content of blood and blood components |
| EP0406485A1 (en) | 1989-07-03 | 1991-01-09 | NPBI Nederlands Produktielaboratorium voor Bloedtransfusieapparatuur en Infusievloeistoffen B.V. | A method for the removal of leukocytes from a leukocyte-containing suspension and filter unit for use with the method |
| US5258126A (en) | 1989-09-12 | 1993-11-02 | Pall Corporation | Method for obtaining platelets |
| US5837539A (en) * | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
| GB9026538D0 (en) | 1990-12-06 | 1991-01-23 | Knight Scient Ltd | Filtration arrangement |
| FR2695563B1 (fr) * | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
| IL104670A (en) * | 1993-02-09 | 1998-04-05 | Travenol Lab Israel Ltd | Leukocyte removal method and filter unit for same |
| GB9307321D0 (en) | 1993-04-07 | 1993-06-02 | Knight Scient Ltd | Method of separating particles from a filter |
| WO1994025873A1 (en) * | 1993-04-23 | 1994-11-10 | Cellpro, Incorporated | Methods for enriching fetal progenitor cells from maternal blood |
| DE69417549T2 (de) | 1993-12-22 | 1999-11-25 | Baxter International Inc., Deerfield | Verfahren zur schätzung des durchschnittlichen faserdurchmessers von unterschiedlichen filtrationsmitteln |
| US5432054A (en) * | 1994-01-31 | 1995-07-11 | Applied Imaging | Method for separating rare cells from a population of cells |
| US6001647A (en) * | 1994-04-28 | 1999-12-14 | Ixion Biotechnology, Inc. | In vitro growth of functional islets of Langerhans and in vivo uses thereof |
| US5972627A (en) * | 1994-06-15 | 1999-10-26 | Systemix, Inc. | Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby |
| GB9413029D0 (en) * | 1994-06-29 | 1994-08-17 | Common Services Agency | Stem cell immobilisation |
| AU700743B2 (en) | 1994-08-31 | 1999-01-14 | Dendreon Corporation | Cell separation apparatus and method |
| US5789148A (en) * | 1994-08-31 | 1998-08-04 | Dendreon Corporation | Cell separation composition |
| JPH08104643A (ja) * | 1994-10-05 | 1996-04-23 | Asahi Medical Co Ltd | 赤血球除去方法 |
| US5647985A (en) * | 1994-10-17 | 1997-07-15 | Baxter International Inc. | Whole blood leukodepletion and platelet filter |
| US5662813A (en) * | 1994-10-21 | 1997-09-02 | Bioseparations, Inc. | Method for separation of nucleated fetal erythrocytes from maternal blood samples |
| US5677136A (en) * | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| US5965457A (en) * | 1995-06-06 | 1999-10-12 | Magnani; John L. | Methods of screening for a candidate compound able to bind to CD34+ cells |
| US6015554A (en) * | 1995-06-07 | 2000-01-18 | Systemix, Inc. | Method of reconstituting human lymphoid and dendritic cells |
| WO1996040875A1 (en) * | 1995-06-07 | 1996-12-19 | Novartis Ag | Methods for obtaining compositions enriched for hematopoietic stem cells and antibodies for use therein |
| US5891443A (en) * | 1995-07-03 | 1999-04-06 | The United States Of America As Represented By The Secretary Of Agriculture | Method to produce granulocyte colony stimulating factor from immortalized avian T lymphocytes to produce immortalized cells |
| WO1997021488A1 (en) | 1995-12-11 | 1997-06-19 | Dendreon Corporation | Cell separation composition, kit and method |
| GB9603249D0 (en) * | 1996-02-16 | 1996-04-17 | Univ Nottingham | Foetal cell analysis |
| JP3322595B2 (ja) * | 1996-03-28 | 2002-09-09 | テルモ株式会社 | フィルター装置および生体微細組織の分離・回収方法 |
| WO1998005795A1 (en) * | 1996-08-02 | 1998-02-12 | The Center For Blood Research, Inc. | Enrichment of dendritic cells from blood |
| CN1330752C (zh) * | 1997-01-24 | 2007-08-08 | 旭化成医疗株式会社 | 细胞分离方法 |
| ATE329012T1 (de) * | 1997-04-08 | 2006-06-15 | Pall Corp | Verfahren zur gewinnung von seltenen zellen aus blutprodukten |
| US6120474A (en) | 1997-12-15 | 2000-09-19 | Nissho Corporation | Blood component-recovering apparatus and a method for recovering blood components using the same |
| US5989441A (en) * | 1997-12-22 | 1999-11-23 | Interferon Science, Inc. | Recovery of functional human leukocytes from recycled filters |
| JP2001161352A (ja) | 1999-12-03 | 2001-06-19 | Asahi Medical Co Ltd | 生体組織再生用細胞の分離方法、生体組織再生用細胞及び生体組織再生用細胞分離装置 |
-
1998
- 1998-04-03 AT AT98913392T patent/ATE329012T1/de active
- 1998-04-03 AU AU67954/98A patent/AU6795498A/en not_active Abandoned
- 1998-04-03 DE DE69834809T patent/DE69834809T2/de not_active Expired - Lifetime
- 1998-04-03 US US09/402,158 patent/US6544751B1/en not_active Expired - Lifetime
- 1998-04-03 EP EP06075344A patent/EP1690930A1/en not_active Withdrawn
- 1998-04-03 EP EP98913392A patent/EP0973873B1/en not_active Expired - Lifetime
- 1998-04-03 CA CA2286156A patent/CA2286156C/en not_active Expired - Lifetime
- 1998-04-03 JP JP54293298A patent/JP4187275B2/ja not_active Expired - Lifetime
- 1998-04-03 WO PCT/US1998/006643 patent/WO1998045413A1/en not_active Ceased
-
2003
- 2003-02-11 US US10/361,586 patent/US20030134417A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1690930A1 (en) | 2006-08-16 |
| AU6795498A (en) | 1998-10-30 |
| JP2001518792A (ja) | 2001-10-16 |
| DE69834809T2 (de) | 2007-05-16 |
| ATE329012T1 (de) | 2006-06-15 |
| CA2286156C (en) | 2013-03-19 |
| CA2286156A1 (en) | 1998-10-15 |
| WO1998045413A1 (en) | 1998-10-15 |
| EP0973873A1 (en) | 2000-01-26 |
| DE69834809D1 (de) | 2006-07-20 |
| EP0973873B1 (en) | 2006-06-07 |
| US20030134417A1 (en) | 2003-07-17 |
| US6544751B1 (en) | 2003-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4187275B2 (ja) | 血液製剤から希少細胞を採集する方法 | |
| EP0987325B1 (en) | Method for separating cells | |
| JP5343110B2 (ja) | 接線流れ濾過デバイス、および幹細胞富化のための方法 | |
| US5635387A (en) | Methods and device for culturing human hematopoietic cells and their precursors | |
| JP3331398B2 (ja) | 不均質な細胞混合物から特定の細胞集団を分離するための方法、装置およびシステム | |
| US4343793A (en) | Process for obtaining intact and viable leucocytes and thrombocytes from blood | |
| KR20120093397A (ko) | 선택적 사이토페레시스 장치 및 그와 관련된 방법 | |
| US20040152190A1 (en) | Method of separating and concentrating cells for kidney regfneration | |
| JPH07503127A (ja) | 幹細胞を選択的に増加する方法 | |
| US20020031757A1 (en) | Method of regenerating a tissue | |
| AU6559094A (en) | Human erythroid progenitor cell population | |
| US7393628B2 (en) | Method for enriching adherent monocyte populations | |
| Smit et al. | Filtration of activated granulocytes during cardiopulmonary bypass surgery: a morphologic and immunologic study to characterize the trapped leukocytes | |
| JP4245324B2 (ja) | 単球の分離回収方法 | |
| US20070248984A1 (en) | Methods and compositions for separating cells | |
| WO2012061291A2 (en) | Methods and compositions for cell separation of blood tissues | |
| JP3938973B2 (ja) | 細胞分離方法 | |
| Kilpatrick | Isolation of lymphocytes and accessory cells for assays of mitogenicity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050328 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050328 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070911 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20070925 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20070925 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071114 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080401 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080626 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080812 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080909 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110919 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120919 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130919 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |